Navigation Links
FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab
Date:2/18/2009

THOUSAND OAKS, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Amgen's submission and filed a Biologics License Application (BLA) for denosumab, an investigational RANK Ligand inhibitor. The indications for which Amgen is seeking FDA approval are treatment and prevention of postmenopausal osteoporosis (PMO) in women and treatment and prevention of bone loss in patients undergoing hormone ablation therapy for either prostate or breast cancer.

The FDA will target an Agency action within ten months of the application's submission date, resulting in a Prescription Drug User Fee Act (PDUFA) action date of Oct. 19, 2009. Due to the interdependency of the data across the indications from more than 11,000 patients, both files will be reviewed simultaneously.

Amgen has also submitted marketing applications for use of denosumab for these indications in the European Union, Canada, Switzerland, and Australia.

About Denosumab

Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts (the cells that break down bone). Denosumab is being investigated for its potential to inhibit all stages of osteoclast activity through a targeted mechanism. Denosumab is being studied in a range of bone loss conditions including PMO and bone loss in patients undergoing hormone ablation for prostate and breast cancer, as well as for its potential to delay bone metastases and inhibit and treat bone destruction across many stages of cancer. Denosumab is also being investigated in rheumatoid arthritis.

Osteoporosis: Impact and Prevalence

Often referred to as the "silent epidem
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
2. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
3. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
4. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
5. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
6. FDA Accepts Immucors Response to Warning Letter
7. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
8. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
9. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
10. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
11. FDA Accepts Ranexa(R) sNDA and NDA for Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... In response to its clients’ ... sales, training and consumer engagement challenges, digital ... applications to turn their clients’ visions into reality. ... mobile app creations, are now featured on its ... with Toyota, StudioPMG created a robust cross-platform mobile ...
(Date:10/1/2014)... California (PRWEB) October 01, 2014 ... the National Science Foundation to expand their bioCAD/CAM software ... build and modify DNA. The Small Business Innovation Research ... the “j5” technology under exclusive license from the Lawrence ... Joint BioEnergy Institute , an LBNL laboratory that develops ...
(Date:9/30/2014)... German . , ... in a semiconductor layer. Quantum dots are small structures that ... a short laser pulse is fired at the photonic crystal, ... a change in the electromagnetic field around it. This change ... by the dot. As soon as the refractive index recovers ...
(Date:9/30/2014)... 30, 2014 Pacific Northwest Biotechnology, LLC ... Global Markets Direct,s, ,Pacific Northwest Biotechnology, LLC ... overview of the Pacific Northwest Biotechnology, LLC,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... analysis at various stages, therapeutics assessment by drug ...
Breaking Biology Technology:Digital Agency Studio PMG Launches New Case Studies on Website 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Ultrafast remote switching of light emission 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3
... gather a burgeoning number of stem cell researchers into ... of Wisconsin-Madison has established the new Wisconsin Stem Cell ... UW-Madison Graduate School, the new initiative is intended to ... develop new resources and opportunities for as many as ...
... announced today that The Valley Hospital , ... in Ridgewood, N.J., has successfully implemented API's Payrollmation time ... ,Payrollmation automates time and attendance data collection and ... will improve employee morale and help the organization to ...
... University of Wisconsin-Madison students will compete for $22,000 ... G. Steve Burrill Technology Business Plan Competition . ... and various other disciplines, will pitch their plans for ... of the competition. , ,Within the UW System, this ...
Cached Biology Technology:UW Madison launches new stem cell research program 2Valley Hospital implements API's solution for 3,500 employees 2Students compete for $22,000 in Tech Business Plan Competition 2Students compete for $22,000 in Tech Business Plan Competition 3
(Date:9/30/2014)... aquatic environment on Earth, but when the climate changes ... the limit. The amount of time needed to adjust ... species cope in the future, reveals a new study ... the scientific journal Proceedings of the Royal Society ... increasing levels of greenhouse gases in the atmosphere. The ...
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra Automation, ... for the biotech and power generation industries, ... RECONN Bioprocess Manager, an easy-to-use and cost-effective ... towards bioprocess development laboratories. ... bioreactor and analyzer systems. Accessing and consolidating ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... the Howard Hughes Medical Institute have succeeded in mapping ... wide range of odors, including vanilla, skunk, fish, urine, ... ?patterns of neural activity represents a significant step in ... receptors in the nose into odor perception in the ...
... What does it take to fathom a proverb ?catch the ... tree"? , According to research led by V. S. Ramachandran, ... University of California, San Diego, a region of the brain ... responsible for the human ability to understand metaphor. , Ramachandran ...
... three months after deciding to create an electronic ... registry and results database using an independent host, ... can be accessed by anyone, anywhere, with no ... patients and healthcare providers ready access to information ...
Cached Biology News:Decoding the logic of olfaction 2Decoding the logic of olfaction 3Decoding the logic of olfaction 4Grasping metaphors: UC San Diego research ties brain area to figures of speech 2Roche clinical trial registry and results database launched 2Roche clinical trial registry and results database launched 3